Ongoing studies for the treatment of CAT in adult patients
| Study . | Study design . | Intervention . | Status . |
|---|---|---|---|
| Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients with Cancer Study (NCT03895502) | RCT | Edoxaban for 3 vs 12 mo | Not yet recruiting |
| Direct Oral Anticoagulants (DOACs) Versus LMWH ± Warfarin for VTE in Cancer (CANVAS; NCT02744092) | RCT | DOAC vs LMWH ± warfarin at therapeutic doses | Recruiting |
| A Randomized Phase II Study to Compare the Safety and Efficacy of Dalteparin Vs Rivaroxaban for Cancer-Associated Venous Thromboembolism (PRIORITY; NCT03139487) | RCT | Rivaroxaban vs dalteparin, both at therapeutic doses | Recruiting |
| Weight-Adjusted Dalteparin for Patients Over 90 kg with Acute Cancer-Associated Venous Thromboembolism (WAVe; NCT03297359) | Prospective cohort | Therapeutic weight-adjusted dalteparin (up to 33 000 units daily) × 1 mo | Recruiting |
| Rivaroxaban in the Treatment of Venous Thromboembolism in Cancer Patients (NCT02583191) | RCT | Rivaroxaban vs LMWH, both at therapeutic doses | Recruiting |
| Apixaban for the Treatment of Venous Thromboembolism in Patients with Cancer (CARAVAGGIO; NCT03045406) | RCT | Apixaban vs dalteparin, both at therapeutic doses | Recruiting |
| A Study of Dabigatran Etexilate as Primary Treatment of Malignancy-Associated Venous Thromboembolism (NCT03240120) | Prospective cohort | Tinzaparin followed by dabigatran 150 mg twice daily | Recruiting |
| Study . | Study design . | Intervention . | Status . |
|---|---|---|---|
| Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients with Cancer Study (NCT03895502) | RCT | Edoxaban for 3 vs 12 mo | Not yet recruiting |
| Direct Oral Anticoagulants (DOACs) Versus LMWH ± Warfarin for VTE in Cancer (CANVAS; NCT02744092) | RCT | DOAC vs LMWH ± warfarin at therapeutic doses | Recruiting |
| A Randomized Phase II Study to Compare the Safety and Efficacy of Dalteparin Vs Rivaroxaban for Cancer-Associated Venous Thromboembolism (PRIORITY; NCT03139487) | RCT | Rivaroxaban vs dalteparin, both at therapeutic doses | Recruiting |
| Weight-Adjusted Dalteparin for Patients Over 90 kg with Acute Cancer-Associated Venous Thromboembolism (WAVe; NCT03297359) | Prospective cohort | Therapeutic weight-adjusted dalteparin (up to 33 000 units daily) × 1 mo | Recruiting |
| Rivaroxaban in the Treatment of Venous Thromboembolism in Cancer Patients (NCT02583191) | RCT | Rivaroxaban vs LMWH, both at therapeutic doses | Recruiting |
| Apixaban for the Treatment of Venous Thromboembolism in Patients with Cancer (CARAVAGGIO; NCT03045406) | RCT | Apixaban vs dalteparin, both at therapeutic doses | Recruiting |
| A Study of Dabigatran Etexilate as Primary Treatment of Malignancy-Associated Venous Thromboembolism (NCT03240120) | Prospective cohort | Tinzaparin followed by dabigatran 150 mg twice daily | Recruiting |
DOAC: direct oral anticoagulant.